Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice supplementary table

Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with
reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort
study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine
departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results
from the DAPA-HF trial. Results: A total of 1595 patients were enrolled, of whom 1199 (75.2%) were
eligible for dapagliflozin. Within 1 year after discharge, 21.6% of patients eligible for dapagliflozin
were rehospitalized for HF and 20.5% died. Full implementation of dapagliflozin led to an absolute risk
reduction of 3.5% for mortality (number needed to treat = 28) and 6.5% (number needed to treat = 15)
for HF readmission. Conclusion: Treatment with dapagliflozin in clinical practice may markedly reduce
mortality and readmissions for HF.

研究目的：评估达格列净（dapagliflozin）在西班牙临床实践中用于射血分数降低型心力衰竭（heart failure, HF）患者的预期疗效。
材料与方法：本项多中心队列研究纳入了西班牙各内科病房中因心力衰竭连续收治住院的50岁及以上患者。本研究基于DAPA-HF临床试验的结果，估算达格列净的预期临床获益。
结果：共计纳入1595例患者，其中1199例（75.2%）符合达格列净的用药指征。出院后1年内，符合达格列净用药指征的患者中，21.6%因心力衰竭再次住院，20.5%死亡。全面应用达格列净可使患者死亡率绝对风险降低3.5%（需治疗人数=28），心力衰竭再住院率绝对风险降低6.5%（需治疗人数=15）。
结论：临床实践中采用达格列净治疗，可显著降低心力衰竭患者的死亡率及再住院率。